Treatment with long acting muscarinic antagonists stimulates serum levels of irisin in patients with COPD

These findings imply that treatment of COPD patients with LAMA increase circulating irisin, thus explaining some of the beneficial extra-pulmonary effects of these drugs when used in the treatment of COPD.